TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc has announced an update regarding its CHESS Depositary Interests (CDIs), with a net increase of 918,810 CDIs over quoted securities for November 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options, restricted stock units, and employee stock purchase plans. The company also reported a decrease in other securities, reflecting strategic adjustments in its stock management, including share repurchases on the NYSE. These movements indicate ResMed’s ongoing efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc is a leading company in the healthcare industry, primarily focused on the development and manufacturing of products for the treatment of sleep apnea and other respiratory disorders. The company is known for its innovative solutions and has a significant presence in the global market, particularly in the United States and Australia.
Average Trading Volume: 1,249,949
Technical Sentiment Signal: Buy
Current Market Cap: A$55.4B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.